Register today for free: https://allergyasthmanetwork.org/webinars-updates/chronic-rhinosinusitis-with-nasal-polyps/
📆March 12, 2026
⏰12pm ET
CE is not available for this webinar. Special thanks to Sanofi-Regeneron, AstraZeneca, and Amgen for sponsoring this educational campaign.
The webinar will be featuring…
- Rhonda Nelson who will be sharing her lived experience navigating diagnosis, treatment, and life with nasal polyps
- Dr. Andrew White, allergist and immunologist, offering clear explanations and practical management tips
We invite patients, caregivers, and health professionals to join this upcoming webinar designed to:
• Raise awareness around CRSwNP
• Enhance understanding of symptoms and treatment options
• Empower individuals with strategies for shared decision-making in clinical care
Chronic Rhinosinusitis with Nasal Polyps is a long-term inflammatory condition that can lead to persistent sinus symptoms like congestion, facial pressure, sinus pain, and reduced sense of smell which can significantly impacting daily functioning and quality of life.
and advancing research that translates into meaningful impact.
Thank you to Healio for highlighting both research abstracts. You can find the articles and more information at:
www.healio.com/news/pulmono...
www.healio.com/news/allergy...
• Outcomes data demonstrate participation in a virtual asthma self-management education program is associated with improved asthma control underscoring the power of accessible, evidence-based education.
At Allergy & Asthma Network, we remain committed to elevating the patient voice
• Survey findings of patient and caregiver preferences for epinephrine options reinforced that a needle free delivery method was preferred when treating anaphylaxis and may reduce hesitation resulting in timely use. Thank you to Aquestive for supporting this research.
This past weekend, we were proud to present Allergy & Asthma Network research at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Conference highlighting two important themes in patient-centered care:
Who is ready for a GREAT
@aaaaiorg.bsky.social 2026 conference? @allergyasthmahq.bsky.social is! We are stocked at booth #1513 with free resources including BRAND NEW infant anaphylaxis symptom guides - English and Spanish! Don’t miss your chance to grab a copy! #AAAAI2026
Special thanks to Amgen, Sanofi, Regeneron for their support on this awareness campaign.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a condition that can affect a person’s ability to smell, if you think you may have CRSwNP or already have a diagnosis, visit our webpage to learn more: allergyasthmanetwork.org/health-a-z/c...
Today, take a moment to help raise awareness for those living with anosmia. If you or someone you love has ongoing smell loss or chronic sinus symptoms, it’s worth getting evaluated.
Awareness leads to diagnosis and a diagnosis leads to better breathing, better smelling, and better quality of life.
Anosmia affects millions worldwide, yet it often goes unnoticed & undiagnosed. One cause is nasal polyps which are soft, noncancerous growths in the sinuses that can block airflow & interfere with smell & taste. Many think it’s just congestion when it may be a treatable inflammatory condition.
Can you imagine a world without smell? For people living with anosmia, this is their reality every day. Today marks #AnosmiaAwarenessDay and we are shining a light on the loss of smell, a symptom that can have a major impact on quality of life.
AFRS is a subtype of chronic rhinosinusitis driven by allergic inflammation and often requires surgery and systemic steroids. For patients, this approval may represent an additional treatment option beyond repeat surgery and systemic steroids.
Read More: www.news.sanofi.us/2026-02-24-S...
Sanofi - Regeneron has announced that Dupixent (dupilumab) has been approved in the U.S. for allergic fungal rhinosinusitis (AFRS) in adults and children ages 6+ with a history of sinonasal surgery. It is the first therapy specifically approved for this condition.
We recognize the importance of continued progress that prioritizes patient needs, safety, and trust across healthcare settings. We are grateful for our continued partnership with Kaléo.
Wishing the Kaléo team continued success in the years ahead!
Congratulations to Kaléo on 25 years of dedication to advancing medication delivery and patient safety. Allergy & Asthma Network is proud to partner with Kaléo on anaphylaxis education and promoting its AUVI-Q epinephrine auto-injector.
🌍 Why culturally responsive care matters for allergy and asthma outcomes
🤝 What ACAAI is doing to grow the allergy workforce, including outreach to HBCUs
Listen on wherever you get your podcasts.
allergyasthmanetwork.org/podcast/acaa...
Produced in partnership with The Itch Podcast.
They also dig into why there are not enough allergists and why representation in medicine matters for allergy and asthma outcomes.
What is discussed:
✨ What the ACAAI does and how it supports patients and clinicians
🏥 Why long wait times to see an allergist are so common
New episode 🎧 Kortney and Dr, Gupta joined by Dr. Cherie Zachary, President of American College of Allergy, Asthma and Immunology (ACAAI), to talk about the future of allergy care.
Dr. Zachary shares her story as both a patient with allergic disease and a doctor.
We remain committed to advocating for clean air and healthier communities nationwide.
Read the full press release here: allergyasthmanetwork.org/press-page/e...
Clean air protections are directly tied to respiratory health outcomes. We urge the Administration to reconsider this repeal and uphold the 2009 air quality standards. Furthermore, we call on Congress to pass clear, long-term legislation that ensures our air remains safe for all Americans.
CEO Lynda Mitchell, MA, CAE noted that removing this scientific and regulatory foundation for controlling greenhouse gas emissions puts patient health at risk especially for children, older adults, and communities already facing higher pollution burdens.
Allergy & Asthma Network has issued a statement opposing the U.S. EPA’s repeal of the 2009 Endangerment Finding, citing serious concerns about the public health impact for people living with asthma, allergies, and related respiratory conditions.
CEO Lynda Mitchell, MA, CAE noted that removing this scientific and regulatory foundation for controlling greenhouse gas emissions puts patient health at risk especially for children, older adults, and communities already facing higher pollution burdens.
To learn more, please contact us or visit our website: trial.autocruitment.com/COMFORT-Todd...
#ClinicalTrial #PeanutAllergy #Sponsored
To take part in this study, your child must:
- Be between 1 & 3 years old
- Have, or likely have, a peanut allergy (based on eval from a doctor)
- Be on a strict peanut-free diet
- Have access to emergency medications (including epinephrine devices) & a current food allergy emergency action plan
Does your toddler have a peanut allergy?
Learn about a clinical study of a skin patch for the treatment of peanut allergy.
If your child has or may have a peanut allergy, we ask you to consider the COMFORT Toddlers study. It may help us learn more about treating peanut allergy in toddlers.
Lynda has stated that although the FDA’s decision was disappointing, she is encouraged that the delay in approval was not because of safety concerns.
Find out more about what this means for those living with #allergies from Healio: www.healio.com/news/allergy...
#Anaphylaxis #PatientAccess #FDA
